Despite the above mentioned challenges in comparing DNA methylation assays, we set out to compare direct-MSP, nested-MSP, pyrosequencing, and MS-HRM to qualitatively and quantitatively analyze RET promoter CpG island methylation and its predictive value in stage II colon cancer patients. The gene discussed is RET; the disease is malignant colon neoplasm.